肺癌免疫治疗新时代新思考-中国肿瘤生物治疗杂志.PDFVIP

中国肿瘤生物治疗杂志 Chin J Cancer Biother, Feb. 2019, Vol. 26, No. 2 ·137 · DOI：：10.3872/j.issn.1007-385x.2019.02.001 ∙专家论坛∙ 肺癌免疫治疗: 新时代，新思考 白日兰，崔久嵬（吉林大学 第一医院肿瘤中心，吉林 长春 130021） [摘 要] 近年来，免疫检查点抑制剂不断被研发及其在临床实践中的应用拓展，迅速改变着肺癌的治疗模式。目前，中国研究 者也踊跃研发多款免疫治疗药物并将其逐渐应用于临床研究，预示着中国已进入免疫治疗新时代。但随着临床研究的不断拓展 及实验数据的不断积累，同时也给我们带来许多新挑战和新思考。本文主要对肺癌免疫治疗模式的突破、免疫治疗临床试验排 除的特殊人群、免疫治疗疗效评价、治疗相关不良反应以及疗效预测标志物等多方面发展现状和挑战进行逐一阐述。 [关键词] 肺癌；免疫治疗；疗效评估；不良反应；生物标志物 [中图分类号] R730.51; R734 [文献标识码] A [文章编号] 1007-385X （2019 ）02-0137-009 Immunotherapy for lung cancer: new era, new thinking BAI Rilan, CUI Jiuwei （Cancer Center, the First Hospital of Jilin University, Changchun 130021, Jilin, China） [Abstract] In recent years, immune checkpoint inhibitors have been continuously researched and developed, and gradually expanded in clinical practice, rapidly changing the treatment mode of lung cancer. At present, a number of immunotherapeutic drugs are also ac- tively developed in China and gradually applied to clinical research, indicating that China has entered a new era of immunotherapy. However, with the continuous expansion of clinical research and the continuous accumulation of experimental data, it also brings us many new challenges and new thinking. This article mainly analyzes the development status and challenges of immunotherapy for lung cancer in the aspects of breakthroughs in treatment modes, special populations excluded from clinical immunotherapy trials, response evaluation, treatment-related adverse events and predictive biomarkers. [Key words] lung cancer; immunotherapy; response evaluation; adverse event; biomarkers [Chin J Cancer Biother, 2019, 26(2): 137-145. DOI ：10.3872/j.issn. 1007-385X.2019.02.001] 崔久嵬 教授、主任医师、博士生导 用于临床研究，2018年纳武单抗（nivolumab）和派姆 师，现任吉林大学第一医院肿瘤中心